Pneumonia detection kit DR1017

colon cancerlipidcarbohydrate antigen 50

CA50 is a kind of carbohydrate antigens with sialic acid lipid and glycoprotein sialic acid as the main components. It is non-organ-specific and a broad-spectrum tumor marker, which is widely in the pancreas, gallbladder, liver, stomach, colorectal rectum, bladder, and uterus. It does not exist in normal tissues. When the cells occur malignant transformation, glycosylation conversion enzyme is inactivated and some invertase has been activated, resulting in cell surface glycosylation structural changes and forming CA50. [INTENDED USE] The kit has been designed for the quantitative determination of Carbohydrate Antigen 50 (CA50) in human serum. The method can be used for samples over the range of 1.0~140.0 U/mL Cancer antigen 50 (CA50) is a glycolipid that is similar to the tumor marker CA19-9; however, CA50 antibodies recognize both the fucosyl form of sialylated Lewis(a) carbohydrate moiety and sialylated Lewis(a) moiety. CA50 is not organ-specific and elevated levels are seen in various conditions such as colitis, pancreatitis, pneumonia, and cancers, especially gastrointestinal cancers (e.g., pancreatic, stomach, hepatic, and colorectal cancers). It can be used as a marker for detecting gastrointestinal cancers, specifically pancreatic and colon cancer. Diagnostic assays for CA50 are based on the antibody sandwich principle using ELISA or CLIA. Cancer-associated carbohydrate antigen 50 (CA50) is a ganglioside glycoprotein and is a biomarker for the diagnosis and prognosis of gastrointestinal malignancies, especially of pancreatic and colorectal cancers .